“The issued patent in the US earlier this year proves the success of our patent strategy. We now hold at least one granted patent from each of our patent applications, whereby the value of our technology is well secured by our intellectual property rights. Based on that, we can now both take the next step in development and also review our portfolio strategy”, says CEO Dr. Hans Arwidsson.
The next study – A strategic move
Both the elderly and young children lack the capability of the immune system found in young adults, why the need of a vaccine adjuvant to stimulate protection against disease is often necessary. Therefore, designing the next study to include elderly is a strategic choice.
“While engaging more adults in our trials is a necessity before we can perform studies among younger children, the choice of elderly in our next phase adds value both by gaining more knowledge of the adjuvant effects in weaker immune systems and also by opening an additional market segment without losing focus on our vision”, says CSO Dr. Anna‑Karin Maltais.
Extended portfolio of nasal vaccines
At the same time, the technology of nasal vaccination can be applied to many more fields, providing advantages as great convenience for the patients, with needle free administration, reduced cost of administration and double protection with antibodies both in the mucosa and blood.
Eurocine Vaccines will therefore continue to evaluate a broadening of its product portfolio both together with partners and stand-alone.
 See this short video, where CSO Dr. Anna-Karin Maltais explains why children are more vulnerable and how the adenoid, an immunological organ, can be better stimulated; https://youtu.be/n40I81B2hog !